These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 12734607)

  • 1. A pilot double-blind randomized placebo-controlled study of molsidomine 16 mg once-a-day in patients suffering from stable angina pectoris: correlation between efficacy and over time plasma concentrations.
    Messin R; Fenyvesi T; Carreer-Bruhwyler F; Crommen J; Chiap P; Hubert P; Dubois C; Famaey JP; Géczy J
    Eur J Clin Pharmacol; 2003 Jul; 59(3):227-32. PubMed ID: 12734607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of molsidomine once-a-day in patients with stable angina pectoris.
    Messin R; Opolski G; Fenyvesi T; Carreer-Bruhwyler F; Dubois C; Famaey JP; Géczy J
    Int J Cardiol; 2005 Jan; 98(1):79-89. PubMed ID: 15676171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute and chronic effect of molsidomine extended release on exercise capacity in patients with stable angina, a double-blind cross-over clinical trial versus placebo.
    Messin R; Boxho G; De Smedt J; Buntinx IM
    J Cardiovasc Pharmacol; 1995 Apr; 25(4):558-63. PubMed ID: 7596123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of once- and twice-daily formulations of molsidomine in patients with stable angina pectoris: double-blind and open-label studies.
    Messin R; Cerreer-Bruhwyler F; Dubois C; Famaey JP; Géczy J
    Adv Ther; 2006; 23(1):107-30. PubMed ID: 16644612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short- and long-term effects of molsidomine retard and molsidomine nonretard on exercise capacity and clinical status in patients with stable angina: a multicenter randomized double-blind crossover placebo-controlled trial.
    Messin R; Karpov Y; Baikova N; Bruhwyler J; Monseu MJ; Guns C; Géczy J
    J Cardiovasc Pharmacol; 1998 Feb; 31(2):271-6. PubMed ID: 9475269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group.
    Thadani U; Ezekowitz M; Fenney L; Chiang YK
    Circulation; 1994 Aug; 90(2):726-34. PubMed ID: 8044941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in the antiischaemic effects of molsidomine and isosorbide dinitrate (ISDN) during acute and short-term administration in stable angina pectoris.
    Wagner F; Gohlke-Bärwolf C; Trenk D; Jähnchen E; Roskamm H
    Eur Heart J; 1991 Sep; 12(9):994-9. PubMed ID: 1936012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled study.
    Sellier P; Broustet JP
    Am J Cardiovasc Drugs; 2003; 3(5):361-9. PubMed ID: 14728070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effect of molsidomine, a direct nitric oxide donor, as an add-on treatment, on endothelial dysfunction in patients with stable angina pectoris undergoing percutaneous coronary intervention: results of the MEDCOR trial.
    Barbato E; Herman A; Benit E; Janssens L; Lalmand J; Hoffer E; Chenu P; Guédès A; Missault L; Pirenne B; Cardinal F; Vercauteren S; Wijns W
    Atherosclerosis; 2015 Jun; 240(2):351-4. PubMed ID: 25875387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic effectiveness of molsidomine in patients with exercise-induced angina pectoris].
    Sinkiewicz W; Dziedziczko A
    Pol Tyg Lek; 1993 Jan 18-25; 48(3-4):80-2. PubMed ID: 8361895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of once-daily molsidomine in coronary patients from two distinct European ethnicities.
    Messin R; Dubois C; Famaey JP
    Adv Ther; 2008 Nov; 25(11):1200-14. PubMed ID: 19002405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-anginal and anti-ischemic effects of the selective beta-blocker talinolol in patients with stable angina pectoris.
    Faulhaber HD; Weigmann I; Lang U; Weinsberg F; Terhaag B
    Int J Clin Pharmacol Ther; 2005 Feb; 43(2):63-70. PubMed ID: 15726874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molsidomine and isosorbide dinitrate: a comparative trial of tolerance in long-term intake by IHD patients with stable angina of effort].
    Alimova EV; Martsevich SIu; Kutishenko NP; Metelitsa VI
    Ter Arkh; 1997; 69(12):37-40. PubMed ID: 9503532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of molsidomine on exercise tolerance in patients with exertional angina pectoris.
    Kinoshita M; Sawamura M; Motomura M; Takayama Y; Kawaguchi Y; Kawakita S
    Jpn Circ J; 1983 Dec; 47(12):1398-405. PubMed ID: 6689183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antianginal effect of molsidomine in prolonged oral therapy. A double blind, crossover, randomized study.
    Baudry C
    Acta Cardiol; 1982; 37(1):23-30. PubMed ID: 7044013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of gallopamil on myocardial microperfusion in patients with stable effort angina: a randomized, cross-over, double-blind, placebo-controlled trial.
    Acanfora D; Vitale DF; Rengo C; Iannuzzi GL; Furgi G; Picone C; Rossi M; Trojano L; Rengo F
    Cardiology; 1997; 88(4):353-60. PubMed ID: 9197430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of a once-daily graded-release diltiazem formulation dosed at bedtime compared to placebo and to morning dosing in chronic stable angina pectoris.
    Glasser SP; Gana TJ; Pascual LG; Albert KS
    Am Heart J; 2005 Feb; 149(2):e1-9. PubMed ID: 15846251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind, randomized, placebo-controlled study of molsidomine in patients with stable effort angina receiving beta-blocker therapy with atenolol.
    De Backer GG; Derese A
    Am Heart J; 1985 Mar; 109(3 Pt 2):678-81. PubMed ID: 3883735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term treatment with the NO-donor molsidomine reduces circulating ICAM-1 levels in patients with stable angina.
    Van Hove C; Carreer-Bruhwyler F; Géczy J; Herman AG
    Atherosclerosis; 2005 Jun; 180(2):399-405. PubMed ID: 15910868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dipyridamole in chronic stable angina pectoris; a randomized, double blind, placebo-controlled, parallel group study.
    Picano E;
    Eur Heart J; 2001 Oct; 22(19):1785-93. PubMed ID: 11549300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.